Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082813 | 0.83 | GRIK1 (0.38) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL13850714 | 0.83 | TSHR (0.60) | CA1CA2TDP1TSHRNPSR1 | |
| SCHEMBL19111958 | 0.82 | DPP7 (0.50) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL4017322 | 0.81 | HDAC7 (0.56) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL13374821 | 0.81 | HDAC7 (0.56) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL28477032 | 0.80 | TDP1 (0.47) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL8373229 | 0.80 | HDAC1 (0.51) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL26296395 | 0.78 | HDAC7 (0.62) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL4015651 | 0.78 | HDAC7 (0.52) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL8373232 | 0.78 | BIRC2 (0.58) | HDAC7HDAC8HDAC6HDAC9HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113769119-B | Medical ultrasonic coupling agent and preparation method thereof | 山东科宏医疗科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-1626707-A4 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | YISSUM RES DEV CO (IL) | 2009-07-01 | — | — | EP | claimed |
| EP-1626707-A2 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | Teva Pharmaceutical Industries Limited (IL) | 2006-02-22 | — | — | EP | claimed |
| EP-1311256-B1 | USE OF DERIVATIVES OF VALPROIC ACID AMIDES AND 2-VALPROENIC ACID AMIDES FOR THE TREATMENT OR PREVENTION OF PAIN AND/OR HEADACHE DISORDERS | TEVA PHARMA (IL) | 2005-08-17 | — | — | EP | claimed |
| US-20040204495-A1 | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment of prevention of pain and/or headache disorders | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2004-10-14 | — | — | US | claimed |
| US-20040175423-A1 | Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-09-09 | — | — | US | claimed |
| US-20040176463-A1 | Immediate release formulation of n-(2-propylpentanoyl)glycinamide | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-09-09 | — | — | US | claimed |
| WO-2004071424-A2 | IMMEDIATE RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL)GLYCINAMIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| WO-2004071421-A2 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| EP-1311256-A4 | USE OF DERIVATIVES OF VALPROIC ACID AMIDES AND 2-VALPROENIC ACID AMIDES FOR THE TREATMENT OR PREVENTION OF PAIN AND/OR HEADACHE DISORDERS | TEVA PHARMA (IL) | 2004-03-24 | — | — | EP | claimed |
| EP-1311256-A2 | USE OF DERIVATIVES OF VALPROIC ACID AMIDES AND 2-VALPROENIC ACID AMIDES FOR THE TREATMENT OR PREVENTION OF PAIN AND/OR HEADACHE DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-05-21 | — | — | EP | claimed |
| US-20020052418-A1 | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-05-02 | — | — | US | claimed |
| WO-2002013766-A2 | VALPROIC ACID DERIVATIVES FOR THE TREATMENT OF PAIN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-02-21 | — | — | WO | claimed |
| EP-0659174-B1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RES DEV CO (IL) | 1999-02-10 | — | — | EP | claimed |
| US-5585358-A | ANTIEPILEPTIC AGENTS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; DYSKINESIA; ANTIISCHEMIC AGENTS | YISSUM RESEARCH DEVELOPMENT CORPORATION OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1996-12-17 | — | — | US | claimed |
| EP-0659174-A4 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS. | YISSUM RES DEV CO (IL) | 1995-09-27 | — | — | EP | claimed |
| EP-0659174-A1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-06-28 | — | — | EP | claimed |
| WO-1995001956-A1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-01-19 | — | — | WO | claimed |
| US-12521426-B2 | Methods and compositions for inhibiting glyoxalase 1 (GLO1) | PALMER ABRAHAM (US) | 2026-01-13 | — | — | US | disclosed |
| WO-1995001956-A1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176463-A1 | Immediate release formulation of n-(2-propylpentanoyl)glycinamide | CACNA1E, GRIK1, GRIN2D | HDAC7 172/4885HDAC8 144/4885HDAC6 139/4885 |
| US-20040204495-A1 | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment of prevention of pain and/or headache disorders | HDAC3, HDAC2, FAAH2 | HDAC7 32/4885HDAC8 16/4885HDAC6 35/4885 |
| US-20040175423-A1 | Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds | CACNA1E, GRIN2C, GRIN2D | HDAC7 243/4885HDAC8 184/4885HDAC6 210/4885 |
| US-20020052418-A1 | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders | HDAC3, HDAC2, FAAH2 | HDAC7 28/4885HDAC8 16/4885HDAC6 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.